Propanc Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PPCB and other ETFs, options, and stocks.

About PPCB

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. 

CEO
James Andrew Nathanielsz
CEOJames Andrew Nathanielsz
Employees
2
Employees2
Headquarters
Camberwell, Victoria (VIC)
HeadquartersCamberwell, Victoria (VIC)
Founded
2007
Founded2007
Employees
2
Employees2

PPCB Key Statistics

Market cap
4.21M
Market cap4.21M
Price-Earnings ratio
-0.01
Price-Earnings ratio-0.01
Dividend yield
Dividend yield
Average volume
139.84K
Average volume139.84K
High today
$0.3722
High today$0.3722
Low today
$0.3062
Low today$0.3062
Open price
$0.3722
Open price$0.3722
Volume
274.16K
Volume274.16K
52 Week high
$145.46
52 Week high$145.46
52 Week low
$0.303
52 Week low$0.303

Stock Snapshot

As of today, Propanc Biopharma(PPCB) shares are valued at $0.32. The company's market cap stands at 4.21M, with a P/E ratio of -0.01.

On 2026-01-19, Propanc Biopharma(PPCB) stock moved within a range of $0.31 to $0.37. With shares now at $0.32, the stock is trading +3.3% above its intraday low and -15.0% below the session's peak.

Trading volume for Propanc Biopharma(PPCB) stock has reached 274.16K, versus its average volume of 139.84K.

Over the past 52 weeks, Propanc Biopharma(PPCB) stock has traded between a high of $145.46 and a low of $0.30.

Over the past 52 weeks, Propanc Biopharma(PPCB) stock has traded between a high of $145.46 and a low of $0.30.

People also own

Based on the portfolios of people who own PPCB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .